Cerebrolysin vs Dihexa.

Cerebrolysin is a peptide preparation produced by the enzymatic breakdown of purified porcine (pig) brain proteins, yielding a mixture of low-molecular-weight peptides and free amino acids. It is manufactured by EVER Neuro Pharma and given by injection or intravenous infusion rather than orally. Marketed as a neurotrophic and neuroprotective agent, it has been studied across acute ischaemic stroke, vascular dementia, Alzheimer's disease and traumatic brain injury. It is one of the most extensively trialed brain-peptide preparations, yet its clinical benefit remains genuinely contested.

Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide; also referenced as PNB-0408) is a small, orally active peptidomimetic derived from angiotensin IV (Ang IV), a C-terminal fragment of the renin-angiotensin system. It was designed at Washington State University by chemically modifying Ang IV to increase lipophilicity and metabolic stability, yielding a brain-penetrant molecule investigated as a procognitive / antidementia research agent. It is a research chemical, not a drug; it has never been an approved medicine.

Because Cerebrolysin is a complex biological mixture rather than a single molecule, its mechanism is described as pleiotropic. The peptide fraction is proposed to mimic endogenous neurotrophic factors, supporting neuronal survival, synaptic plasticity and neurogenesis. Preclinical work also suggests reduced excitotoxicity, anti-apoptotic signaling and effects on amyloid processing. The precise active components and their targets in humans are not fully defined.

Dihexa was developed from Ang IV, whose procognitive effects were originally studied at the AT4/IRAP site, but its proposed primary mechanism is potentiation of hepatocyte growth factor (HGF) signaling through its receptor tyrosine kinase c-Met, which drives dendritic spine formation (spinogenesis) and synaptogenesis in hippocampal neurons. Activating HGF/c-Met is thought to remodel synaptic connectivity rather than act as a classical neurotransmitter. Important caveat: the central biochemical evidence that dihexa works by binding HGF and augmenting HGF/c-Met activation came from a paper that has since been retracted for data fabrication, so the molecular mechanism should be treated as unproven. The downstream behavioral phenotype (improved spatial learning in rodents) was reported in separate, non-retracted work.

Cerebrolysin has been evaluated in numerous randomized controlled trials, and two Cochrane systematic reviews summarize the best available evidence. The 2023 Cochrane review of acute ischaemic stroke concluded that Cerebrolysin probably has little or no beneficial effect on death or clinical outcome, and it flagged a possible increase in non-fatal serious adverse events, rating certainty of evidence as low to moderate. The 2019 Cochrane review of vascular dementia found possible short-term benefits on cognition and global function but did not recommend routine use, citing small trials, short follow-up and high risk of bias. Several included trials were industry-sponsored, which further tempers confidence. Taken together, the clinical picture is mixed and unsettled rather than clearly positive. The underlying trial set has a distinctive geography: a large share of the randomized evidence originates from centers in Eastern Europe, the CIS, China and parts of Asia, often with the manufacturer as sponsor or provider of study drug, and a substantial portion of the earlier literature was published in languages other than English, which complicates independent appraisal. Trial durations are typically short, on the order of weeks of treatment with follow-up rarely extending to a year, and outcome scales differ between studies, which limits pooling. Later work has continued in narrower settings: a randomized pilot study of speech therapy combined with Cerebrolysin for nonfluent aphasia after acute ischaemic stroke was published in Stroke in 2025, and clinical reviews of neuroprotective and neuroregenerative agents after severe traumatic brain injury continue to describe the evidence as inconclusive. What remains unknown is central rather than peripheral: the active components of the mixture are not identified, so batch-to-batch consistency cannot be verified by potency assay against a defined molecule, and no biomarker predicts response. Even so, Cerebrolysin is the best-studied compound in the animal-tissue peptide category by a wide margin, since preparations such as cortexin, thymalin and vilon have no comparable body of randomized evidence and have never been assessed by Cochrane.

There is NO human data on dihexa: no completed clinical trials, no published human pharmacokinetics or safety. The non-retracted foundational study (McCoy et al., J Pharmacol Exp Ther 2013, PMID 23055539) reported that orally administered dihexa reversed scopolamine-induced learning deficits and improved Morris water maze performance in aged (24-month) rats, and induced spinogenesis in cultured hippocampal neurons at picomolar concentrations. Later angiotensin-IV-analog work continued in disease models (e.g., a 2024 study of an Ang IV analog in a 3-nitropropionic-acid Huntington's-like rat model, PMID 38489193). Crucially, the most-cited mechanistic paper tying dihexa's cognitive effects to HGF/c-Met (Benoist et al., J Pharmacol Exp Ther 2014, PMID 25187433) was RETRACTED in 2025 (retraction notice PMID 40312093) after a Washington State University investigation found falsified/fabricated figure data; the widely repeated "thousands of times more potent than BDNF" claim derives from this now-discredited line of work and should not be cited as established fact. The honest summary: rodent behavioral evidence exists, but the headline mechanistic and potency claims rest partly on retracted literature, and human efficacy is entirely unestablished.

In trials Cerebrolysin was generally reported as well tolerated, with reactions such as dizziness, headache, agitation, sweating and injection-site effects. Cochrane reviewers noted a possible signal of increased non-fatal serious adverse events in the stroke setting, though this finding was uncertain, and that uncertainty is itself a finding: the trials were not individually powered for safety, adverse-event definitions varied between studies, and reporting completeness differed, so the signal can be neither confirmed nor dismissed from the existing data. As a porcine-derived biological given parenterally, allergic and hypersensitivity reactions are a theoretical concern, and product information in the countries where it is registered describes contraindications including known hypersensitivity, status epilepticus and severe renal impairment. Rapid infusion has been associated with transient reactions such as flushing, dizziness and palpitations. Because the preparation is a complex mixture rather than a single characterized molecule, immunogenicity and lot-to-lot variability are harder to evaluate than for a defined peptide drug. Material obtained outside licensed pharmacy channels adds contamination and counterfeit risk on top of the pharmacological questions, since parenteral products require verified sterility and endotoxin limits. Adequate monitoring in a trial setting includes supervised administration, observation for infusion reactions, renal function assessment, seizure history review and systematic adverse-event capture. It is a clinical product, not a dietary supplement, and any use is a medical decision.

No human safety data exist; there is no published clinical adverse-event profile, and dihexa is sold only as a research chemical of variable purity. The principal theoretical concern follows directly from its proposed mechanism: c-Met is a validated oncology target because aberrant HGF/c-Met signaling promotes tumor proliferation, invasion, angiogenesis, and metastasis, so a chronic c-Met potentiator raises an unresolved oncogenic-risk question that no human study has addressed. Its reported long circulating half-life and high lipophilicity also mean tissue accumulation and off-target effects are poorly characterized. Because foundational mechanistic data were retracted for fabrication, even the basic biology underlying any risk assessment is uncertain.

Cerebrolysin is not approved by the US FDA and is not marketed in the United States. It is registered and used clinically in a number of countries across Europe, Asia, the CIS and Latin America. This entry is educational only and contains no dosing guidance.

Dihexa is investigational/research-use-only: it is not approved by the FDA or any major regulator for any indication, has no DailyMed monograph, and has not completed human clinical trials. It is not a dietary supplement and is widely sold only as a "research chemical." It is not a WADA-listed named substance, though non-approved experimental compounds are broadly disallowed in sport.